In this issue:
Trends and outcomes during 25 years of allogeneic haematopoietic stem cell transplantation in Europe
The safety and efficacy of autologous hematopoietic stem cell transplantation as a first-line treatment approach in elderly MM patients
Can mobilisation chemotherapy with ASCT be considered an effective and safe treatment option in fit, elderly patients with MM?
Monoclonal antibody therapy in MM: a review of the data for elotuzumab and daratumumab
Early lesional sFF changes and the use of functional MRI to assess response
Dutch population-based study demonstrates a higher risk of SBP patients developing MM following local radiotherapy
Comparing thalidomide and lenalidomide in patients with MM REP - assessing the optimal dose, efficacy and safety in lenalidomide-refractory MM patients
Histone deacetylase (HDAC) inhibitors in RRMM - assessing the safety and preliminary activity of the combination of ricolinostat with lenalidomide and dexamethasone
Defining the role of MAF and GSK3 in the resistance of t(14;16) MM to proteasome inhibition
Please login below to download this issue (PDF)